US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.20

+0.120011.11%

Post-market: 1.13-0.0696-5.80%16:28 EDT

Volume:738.14K

Turnover:902.98K

Market Cap:169.69M

PE:5.60

High:1.32

Open:1.16

Low:1.10

Close:1.08

52wk High:27.36

52wk Low:1.04

Shares:141.41M

Float Shares:36.77M

Volume Ratio:4.17

T/O Rate:2.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

EPS(LYR):-5.8037

ROE:-871.42%

ROA:-49.99%

PB:-8.97

PE(LYR):-0.21

Loading ...

Overview Company News Filings

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Veraxa Biotech Expands FDA-Aligned Non-Animal Testing Models, Aiming to Cut Animal Use in Oncology R&D

Veraxa Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

THOMSON REUTERS

Veraxa Biotech Director Warren Hosseinion Acquires 6,024 Common Shares Worth $10,060.08

VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

Veraxa Biotech Files Initial Beneficial Ownership Statement for CFO Raju Sudir Willener

Veraxa Biotech Names Raju Willener as CFO

Veraxa Biotech Appoints Raju Willener as Chief Financial Officer

THOMSON REUTERS

Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise

THOMSON REUTERS

Veraxa Biotech Ag: Co & Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate Alliance

THOMSON REUTERS

Veraxa Biotech, Secarna announce initial results from AOC alliance

Veraxa Biotech, Secarna Hit in Vitro Milestone in Antibody-Oligonucleotide Conjugate Alliance

Veraxa Biotech Files Form 3 for Interim CFO Carl Von Halem

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/VRXA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.2,"timestamp":1791403200000,"preClose":1.08,"halted":0,"volume":738135,"hourTrading":{"tag":"盘后","latestPrice":1.1304,"preClose":1.2,"latestTime":"16:28 EDT","volume":9792,"amount":11460.405024,"timestamp":1791404920151,"change":-0.0696,"changeRate":-0.058,"amplitude":0.083333},"delay":0,"changeRate":0.111111111111111,"floatShares":36767500,"shares":141407813,"eps":0.2142,"marketStatus":"Post-Mkt","change":0.12,"latestTime":"10-07 16:32:54 EDT","open":1.16,"high":1.32,"low":1.1001,"amount":902981,"amplitude":0.203611,"askPrice":1.21,"askSize":561,"bidPrice":1.1,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.08,"preHourTrading":{"tag":"盘前","latestPrice":1.1448,"preClose":1.08,"latestTime":"09:29 EDT","volume":36080,"amount":42249.665568000004,"timestamp":1791379766006,"change":0.0648,"changeRate":0.06,"amplitude":0.148148},"postHourTrading":{"tag":"盘后","latestPrice":1.1304,"preClose":1.2,"latestTime":"16:28 EDT","volume":9792,"amount":11460.405024,"timestamp":1791404920151,"change":-0.0696,"changeRate":-0.058,"amplitude":0.083333},"volumeRatio":4.171131},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":36767500,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":4.171131,"shares":141407813,"dividePrice":0,"high":1.32,"amplitude":0.203611,"preClose":1.08,"low":1.1001,"week52Low":1.04,"pbRate":"-8.97","psRate":"6037.35","week52High":27.36,"institutionHeld":0,"latestPrice":1.2,"committee":0.977809,"eps":0.2142,"divideRate":0,"volume":738135,"delay":0,"ttmEps":0.2142,"open":1.16,"prevYearClose":18.65,"prevWeekClose":1.13,"prevMonthClose":1.25,"prevQuarterClose":1.25,"fiveDayClose":1.25,"twentyDayClose":1.59,"sixtyDayClose":2.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-10-06","current":5.602241,"percent":0.6875,"low":-3.022108,"twenty":-2.642672,"median":-2.428312,"eighty":-1.301404,"high":-0.413162,"avg":-2.058731,"sd":0.759084,"marketCap":159790828},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-04","current":-2.622384,"twenty":-1.391748,"median":-1.265172,"eighty":-0.552029,"marketCap":216353953},{"date":"2026-09-11","current":-2.842124,"twenty":-2.738773,"median":-1.34261,"eighty":-1.03732,"marketCap":233322891},{"date":"2026-09-18","current":-2.57236,"twenty":-2.751957,"median":-2.365287,"eighty":-1.181392,"marketCap":207869485},{"date":"2026-09-25","current":-2.481882,"twenty":-2.738773,"median":-2.472656,"eighty":-1.249249,"marketCap":199385016},{"date":"2026-10-02","current":-2.09825,"twenty":-2.642883,"median":-2.446678,"eighty":-1.281094,"marketCap":168275297},{"date":"2026-10-06","current":-1.992696,"twenty":-2.642672,"median":-2.428312,"eighty":-1.301404,"marketCap":159790828}],"updateTime":1791405174907},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673014180","title":"VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673014180?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:00","pubTimestamp":1791392422,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, October 7th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA), a developer of next-generation antibody-based cancer the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NDX","BK4139","JEPQ","BK4588","XBI","NVIW.SI","NQmain","TQQQ","LABU","BK4581","QYLG","QQQ","QID","GPIQ","TQQY","QQQM",".IXIC","BK4585","MNQmain","FTEC","PSQ","QQQA","QDTE","QQQE","03086","TECS","QQQJ","QLD","VRXA","SQQQ","QQQY","IYW","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013460","title":"Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013460","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013460?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:09","pubTimestamp":1791378540,"startTime":"0","endTime":"0","summary":"Since going public, Veraxa Biotech has endured a deep slump that has pushed its stock into single-digit territory. Its recovery may hinge on the adoption of new drug-testing protocols to accelerate it","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","AZNH","LU0456855351.SGD","LU1923622614.USD","AZN","BK4566","LU1162221912.USD","LU0912757837.SGD","IE00B19Z3581.USD","IYH","RXL","JDOC","VRXA","IE00BN8TJ469.HKD","MEDX","LU1839511570.USD","ABBV","LU2456880835.USD","SG9999001440.SGD","LU1934455194.USD","BK4581","LU1929549753.HKD","LU2089284900.SGD","LU1720051017.SGD","LU0198837287.USD","XLV","BK4534","TRUH","PJP","GLAM","LU0949170772.SGD","LU1720051108.HKD","PPH","AGNG","IE00B3PB1722.GBP","LU1057294990.SGD","LU2133065610.SGD","IE00BLSP4452.SGD","LU0942090050.USD","XBI","FTXH","IXJ","LU0122379950.USD","VHT","LU2125909247.SGD","FHLC","LU0114720955.EUR","LU2237443465.HKD","LU1829250122.USD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673109209","title":"Veraxa Biotech Expands FDA-Aligned Non-Animal Testing Models, Aiming to Cut Animal Use in Oncology R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2673109209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673109209?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:00","pubTimestamp":1791370854,"startTime":"0","endTime":"0","summary":"Veraxa Biotech expands FDA-aligned non-animal testing models, aiming to cut animal use in oncology R&DVeraxa outlined an ESG-linked shift to FDA-aligned New Approach Methodologies to cut animal testin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL8MQ7sC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","IE00BQXX3F31.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","NDAQ","BK4585","SG9999014005.SGD","BK4139","BK4112","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673409206","title":"Veraxa Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673409206","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673409206?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:00","pubTimestamp":1791370800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUAB2KMJN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671422472","title":"Veraxa Biotech Director Warren Hosseinion Acquires 6,024 Common Shares Worth $10,060.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2671422472","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671422472?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:13","pubTimestamp":1790712788,"startTime":"0","endTime":"0","summary":"Veraxa Biotech director Warren Hosseinion acquires 6,024 common shares worth $10,060.08Veraxa Biotech director Warren Hosseinion reported buying 6,024 ordinary shares at USD 1.67.Stake rose to 634,692","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDLb5hrhn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veraxa Biotech Director Warren Hosseinion Acquires 6,024 Common Shares Worth $10,060.08","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123738","title":"VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123738","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123738?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:30","pubTimestamp":1790091024,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, September 22nd, 2026, FinanceWire VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platf...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-oncology-pipeline-around-bitac-platform-public-market-story-enters-next-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-oncology-pipeline-around-bitac-platform-public-market-story-enters-next-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QID","NDX","QYLG","JEPQ","QQQE","R","BK4022","IYW","NQmain","TECS","FTEC","BK4588","GPIQ","QQQA","BK4585","QLD","ONEQ","BK4139","MNQmain","QQQM","QQQY","TQQQ",".IXIC","PSQ","SQQQ","QQQ","QDTE","TQQY","BK4232","03086","XBI","BK4581","NVIW.SI","VRXA","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668492097","title":"VERAXA Biotech (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2668492097","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668492097?lang=en_us&edition=fundamental","pubTime":"2026-09-19 02:31","pubTimestamp":1789756268,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, September 18th, 2026, FinanceWire VERAXA has appointed Raju Willener as Chief Financial Officer, effective immediatel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-adds-capital-markets-veteran-as-cfo-while-advancing-bitac-oncology-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-adds-capital-markets-veteran-as-cfo-while-advancing-bitac-oncology-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQA","NDX","BK4588","XBI","GPIQ","JEPQ","QLD","SQQQ","QQQ","BK4581","NVIW.SI","TQQY","QQQY","BK4585","QQQE","MNQmain","TECS","FTEC","QQQJ","QQQM",".IXIC","IYW","VRXA","03086","TQQQ","QID","QDTE","BK4139","NQmain","ONEQ","QYLG","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668987897","title":"VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2668987897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668987897?lang=en_us&edition=fundamental","pubTime":"2026-09-17 00:30","pubTimestamp":1789576207,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, September 16th, 2026, FinanceWire VERAXA is developing antibody-based cancer therapies aimed at improving the therape...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-building-a-new-approach-to-precision-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-building-a-new-approach-to-precision-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","03086","QQQE","JEPQ","BK4581","BK4139","SQQQ","NDX","NQmain","ONEQ","GPIQ",".IXIC","QQQ","QID","QQQA","TECS","QQQM","QQQJ","NVIW.SI","XBI","PSQ","BK4588","QYLG","VRXA","QLD","TQQY","QQQY","FTEC","BK4585","MNQmain","IYW","QDTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667069304","title":"Veraxa Biotech Files Initial Beneficial Ownership Statement for CFO Raju Sudir Willener","url":"https://stock-news.laohu8.com/highlight/detail?id=2667069304","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667069304?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:10","pubTimestamp":1789416652,"startTime":"0","endTime":"0","summary":"Veraxa Biotech files initial beneficial ownership statement for CFO Raju Sudir WillenerVeraxa Biotech filed an initial Form 3 disclosing Chief Financial Officer Raju Sudir Willener as a reporting insi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3s2Bxc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336297","title":"Veraxa Biotech Names Raju Willener as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336297","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664336297?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:00","pubTimestamp":1788519621,"startTime":"0","endTime":"0","summary":"Veraxa Biotech names Raju Willener as CFOVeraxa Biotech appointed Raju Willener as chief financial officer, effective immediately, reporting to CEO Christoph Antz.Willener previously served as directo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL15nJ5k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","BK4585","BK4588","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4139","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BQXX3C00.GBP","VRXA","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238336","title":"Veraxa Biotech Appoints Raju Willener as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238336","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664238336?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:00","pubTimestamp":1788519600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA6WQX6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888755","title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888755","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888755?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207055,"startTime":"0","endTime":"0","summary":"Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650Veraxa Biotech CEO, director Christoph Rudiger Antz reported a purchase of 5,000 ordinary shares.The shares were bought at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5ghMkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530737","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:00","pubTimestamp":1787670008,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 25th, 2026, FinanceWire Following completion of the initial phase of its collaboration with OmniAb, VERAXA wil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FTEC","QQQJ","NDX","TQQY","BK4588",".IXIC","IYW","JEPQ","QDTE","QQQ","TQQQ","BK4585","NQmain","XBI","MNQmain","ONEQ","SQQQ","QYLG","QQQA","VRXA","BK4581","QID","QQQE","GPIQ","QLD","QQQY","NVIW.SI","TECS","PSQ","QQQM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662083312","title":"VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision","url":"https://stock-news.laohu8.com/highlight/detail?id=2662083312","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662083312?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:00","pubTimestamp":1787590833,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 24th, 2026, FinanceWire VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JEPQ","NVIW.SI","QYLG","QQQY","FTEC","MNQmain","QQQJ","TECS","TQQQ","ONEQ","SQQQ",".IXIC","QID","BK4588","BK4581","QQQA","PSQ","QQQE","XBI","QQQ","BK4139","QDTE","VRXA","TQQY","QLD","QQQM","NQmain","NDX","IYW","BK4585","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427591","title":"Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661427591?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:41","pubTimestamp":1787571679,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L08R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275959","title":"Veraxa Biotech Ag: Co & Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275959?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:41","pubTimestamp":1787571679,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L08R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727583","title":"Veraxa Biotech, Secarna announce initial results from AOC alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727583","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727583?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:16","pubTimestamp":1787570169,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generation ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-secarna-announce-initial-results-from-aoc-alliance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-secarna-announce-initial-results-from-aoc-alliance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","VRXA","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273390","title":"Veraxa Biotech, Secarna Hit in Vitro Milestone in Antibody-Oligonucleotide Conjugate Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273390","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273390?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569224,"startTime":"0","endTime":"0","summary":"Veraxa Biotech, Secarna hit in vitro milestone in antibody-oligonucleotide conjugate allianceVeraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9ymxP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","LU0314104364.USD","VRXA","SG9999014013.SGD","IE00BQXX3F31.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","BK4585","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661234428","title":"Veraxa Biotech Files Form 3 for Interim CFO Carl Von Halem","url":"https://stock-news.laohu8.com/highlight/detail?id=2661234428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661234428?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:00","pubTimestamp":1787256059,"startTime":"0","endTime":"0","summary":"Veraxa Biotech files Form 3 for Interim CFO Carl von HalemInterim CFO Carl von Halem filed an initial Form 3 for Veraxa Biotech AG, dated July 10, 2026.Disclaimer:This news brief was created by Public","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL7C4F43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656766","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656766","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656766?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:00","pubTimestamp":1786035614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 6th, 2026, FinanceWire The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC&r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-while-expanding-patent-portfolio-for-next-generation-antibody-technologies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-while-expanding-patent-portfolio-for-next-generation-antibody-technologies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","FTEC","IYW","QQQY","SQQQ","XBI","BK4585","TECS","BK4581","QID","QQQE","GPIQ","JEPQ","VRXA","QYLG","ONEQ","QQQ","QLD","NQmain","QDTE","MNQmain","BK4139","PSQ","QQQM","QQQA","BK4588",".IXIC","NVIW.SI","NDX","TQQQ","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":80,"code":"91000000","status":"200"}]}}